Evolent Health Files 8-K on Security Holder Vote

TL;DR

EVH filed an 8-K for a shareholder vote on June 6th.

AI Summary

Evolent Health, Inc. filed an 8-K on June 11, 2024, reporting on a matter submitted to a vote of security holders on June 6, 2024. The filing details the company's corporate information, including its principal executive offices in Arlington, Virginia, and its fiscal year end of December 31.

Why It Matters

This filing indicates a formal process involving shareholder decisions, which can impact corporate governance and future strategic directions.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote, not indicating any immediate financial distress or significant operational change.

Key Numbers

• 001-37415 — Commission File Number (SEC File Number for Evolent Health, Inc.)
• 32-0454912 — IRS Number (Employer Identification Number for Evolent Health, Inc.)

Key Players & Entities

• Evolent Health, Inc. (company) — Registrant
• 0001628908-24-000080 (filing_id) — Accession Number
• June 6, 2024 (date) — Date of earliest event reported
• June 11, 2024 (date) — Date of Report
• Arlington, Virginia (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.01 — tock of Evolent Health, Inc., par value $0.01 per share EVH New York Stock Exchange

Filing Documents

• evh-20240606.htm (8-K) — 58KB
• 0001628908-24-000080.txt ( ) — 184KB
• evh-20240606.xsd (EX-101.SCH) — 2KB
• evh-20240606_lab.xml (EX-101.LAB) — 22KB
• evh-20240606_pre.xml (EX-101.PRE) — 13KB
• evh-20240606_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders (a) Evolent Health, Inc. (the "Company") held its 2024 annual meeting of stockholders on June 6, 2024. At the 2024 annual meeting, the Company's stockholders voted on four proposals. The proposals are described in the Company's definitive proxy statement on Schedule 14A for the 2024 annual meeting filed with the Securities and Exchange Commission on April 26, 2024. (b) The final voting results with respect to each proposal voted upon at the 2024 annual meeting are set forth below. Proposal 1 The Company's stockholders elected ten director nominees named in the proxy statement to the Board of Directors for a one-year term expiring at the Company's 2025 annual meeting of stockholders and until their respective successors are duly elected and qualified, as set forth below: For Against Abstentions Broker Non-Votes Toyin Ajayi, MD 103,554,974 80,525 61,408 6,300,221 Craig Barbarosh 103,220,693 414,817 61,396 6,300,222 Seth Blackley 103,266,119 368,108 62,679 6,300,222 M. Bridget Duffy, MD 101,835,947 1,799,562 61,397 6,300,222 Russell Glass 103,624,139 7,718 65,049 6,300,222 Peter Grua 99,725,657 3,909,853 61,396 6,300,222 Diane Holder 94,993,507 8,642,002 61,396 6,300,223 Richard Jelinek 103,531,067 104,432 61,406 6,300,223 Kim Keck 102,433,640 1,200,665 62,601 6,300,222 Cheryl Scott 102,077,236 1,558,263 61,406 6,300,223 Proposal 2 The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2024, as set forth below: For Against Abstentions 109,895,108 15,998 86,021 Proposal 3 The Company's stockholders approved the compensation of our named executive officers for 2023 on an advisory basis, as set forth below: For Against Abstentions Broker Non-Votes 97,716,171 5,954,639 26,096 6,300,222 Proposal 4 The Company's stockholders selected the frequ

View Full Filing

View this 8-K filing on SEC EDGAR